Welcome to our dedicated page for SHOULDER INNOVATIONS SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
SHOULDER INNOVATIONS, INC. director and CEO Robert Joseph Ball exercised stock options to acquire 10,000 shares of Common Stock at $2.4804 per share. Following the transaction, he directly holds 300,018 common shares.
His stock option position stands at 309,756 options after the exercise, with these options expiring on May 17, 2033. A footnote explains that his current share count includes 4,400 shares received from Cultivate MD Capital Fund I, LLC and 6,752 shares from Genesis Investment Holdings as in-kind distributions, in addition to the 278,866 shares previously reported as directly owned.
Shoulder Innovations, Inc. is holding its 2026 virtual annual stockholder meeting on June 26, 2026 at 3:00 p.m. Eastern Time. Stockholders of record as of April 27, 2026, holding 20,727,949 common shares, may vote on two proposals: electing two Class I directors and ratifying Deloitte & Touche LLP as independent auditor for 2026.
The proxy details board structure, committee memberships, director compensation, related‑party transactions, and 2025 executive pay, including salary, stock options, and cash bonuses under the company’s performance‑based incentive plan.
Shoulder Innovations, Inc. announced the full commercial launch of its InSet™ I-135RFX Humeral Stem, expanding its I-Series shoulder implant portfolio. This launch follows a successful limited market release and FDA 510(k) clearance for additional fracture indications.
The InSet™ I-135RFX can now be used in primary, revision, and fracture total shoulder arthroplasty procedures, in both anatomic and reverse configurations. It joins the InSet™ 95 and InSet™ 70, launched in 2024 and 2025, and is built on the company’s lateral-lateral implant philosophy aimed at reducing complications and improving post-operative range of motion.
Shoulder Innovations, Inc. Chief Operating Officer Matthew Fraser Ahearn exercised stock options to acquire a total of 21,664 shares of common stock on April 20, 2026, at exercise prices of $2.8620 and $2.4804 per share. Following these exercises, he directly holds 286,765 common shares. No open-market sales were reported in this filing.
Shoulder Innovations, Inc. entered into a new long-term lease for a purpose-built corporate headquarters. The company agreed with Ventura Office Park Lot #8, LLC to have a roughly 15,200-square-foot office and warehouse building constructed in Byron Center, Michigan.
The lease runs for an initial 10-year term, with two additional five-year extension options and certain expansion rights. Estimated aggregate rent over the initial term is about $4.4 million. The company has paid a $33.0 thousand security deposit and a further $0.5 million down payment toward construction costs. Possession is expected around the fourth quarter of 2027, after a certificate of occupancy is issued and the landlord substantially completes its work.
SHOULDER INNOVATIONS, INC. Chief Financial Officer Jeffrey S. Points increased his stake through option exercises and a share purchase. On March 13, 2026, he exercised stock options to acquire 13,264 shares of common stock at $2.4804 per share, converting a derivative position into stock. He also made an open-market purchase of 2,000 common shares at $15.00 per share the same day. Following these transactions, he holds 70,785 common shares directly and 50 shares indirectly held by his son. The exercised option was part of a grant that vests in 31 equal monthly increments beginning on March 31, 2025.
Shoulder Innovations director Paul Buckman exercised stock options to acquire 45,606 shares of Common Stock on March 13, 2026. He exercised 19,401 options at $2.4804 per share and 26,205 options at $2.0988 per share. To cover tax obligations, 7,006 shares were withheld in transactions priced at $14.62 and $14.82 per share. After these compensation-related transactions, Buckman directly holds 58,704 shares of Shoulder Innovations common stock.
Shoulder Innovations director Richard Buchholz reported an open-market purchase of 1,000 shares of common stock at $14.84 per share. This buy increased his direct ownership to 13,666 common shares. The transaction was classified as a standard open-market purchase, indicating he used personal capital to add to his position.
SHOULDER INNOVATIONS, INC. CEO & Executive Chairman Robert Joseph Ball bought 2,200 shares of Common Stock in an open-market transaction. The weighted average purchase price was $15.1782 per share, with individual trades ranging from $14.80 to $15.50. After this purchase, he directly owns 278,866 shares.